NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 66 resultados LastUpdate Última actualización 17/07/2018 [14:06:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS

NºPublicación: US2018193481A1 12/07/2018

Solicitante:
OBI PHARMA INC [TW]

Resumen de: US2018193481A1

Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testicle cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.



traducir


 

USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO1,2-CQUINAZOLINES FOR TREATING LYMPHOMAS

NºPublicación: US2018193349A1 12/07/2018

Solicitante:
BAYER PHARMA AG [DE]

Resumen de: US2018193349A1

Described herein are pharmaceutical combinations and compositions comprising a) a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or a salt thereof, and b) one more additional active agents. The pharmaceutical combinations described herein may be useful for treating non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); or peripheral T-cell lymphoma (PTCL).



traducir


 

ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF

NºPublicación: US2018194828A1 12/07/2018

Solicitante:
ACCELERON PHARMA INC [US]

Resumen de: US2018194828A1

In certain aspects, the present invention provides compositions and methods for promoting hone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.



traducir


 

PYRAZOLO3,4-bPYRIDINE AND PYRROLO2,3-bPYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE

NºPublicación: US2018194762A1 12/07/2018

Solicitante:
PHARMACYCLICS LLC [US]

Resumen de: US2018194762A1

Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.



traducir


 

METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA

NºPublicación: US2018194739A1 12/07/2018

Solicitante:
DANA FARBER CANCER INST INC [US]

Resumen de: WO2015089479A1

The present invention provides compounds of any one of Formulae (A), (I-11), (II), and (V) (e.g., compounds of Formula (A-1)-(A-18)), and methods for treating Waldenström's macroglobulinemia (WM) and other B cell neoplams in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin-1 receptor-associated kinase 1 (IRAK1), interleukin-1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase-1 (TAK1), and/or a Src family kinase.



traducir


 

CILIARY NEUROTROPHIC FACTOR RECEPTOR LIGANDS AND METHODS OF USING THE SAME

NºPublicación: WO2018128745A1 12/07/2018

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: WO2018128745A1

Provided are ciliary neurotrophic factor receptor (CNTFR) ligands. In certain aspects, a CNTFR ligand of the present disclosure exhibits increased affinity for CNTFR relative to the corresponding wild-type CNTFR ligand. In certain aspects, a CNTFR ligand of the present disclosure results in reduced binding affinity of glycoprotein 130 (gp130), leukemia inhibitory factor receptor (LIFR), or both, for a complex including the CNTFR ligand and CNTFR, relative to the binding affinity for a complex including the corresponding wild-type CNTFR ligand and CNTFR. In certain aspects, a CNTFR ligand of the present disclosure has both of the aforementioned properties. Also provided are pharmaceutical compositions including the CNTFR ligands, as well as methods of using the CNTFR ligands.



traducir


 

ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF

NºPublicación: WO2018127184A1 12/07/2018

Solicitante:
CENTAURUS BIOPHARMA CO LTD [CN]

Resumen de: WO2018127184A1

The present invention relates to a compound of formula (I) and a pharmaceutical composition and preparation method thereof. The compound can be used as an ALK inhibitor for treating an ALK-mediated disease. The present invention also relates to the use of the compound of formula (I) and the pharmaceutical composition thereof in the preparation of a drug for treating an ALK-mediated disease.



traducir


 

Bromodomain and extra-terminal protein inhibitor combination therapy

NºPublicación: AU2016379347A1 12/07/2018

Solicitante:
CELGENE QUANTICEL RESEARCH INC

Resumen de: AU2016379347A1

The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administration of a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the BET inhibitor or the chemotherapeutic agent alone.



traducir


 

Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant

NºPublicación: AU2016378482A1 12/07/2018

Solicitante:
SYNTHON B V

Resumen de: AU2016378482A1

The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.



traducir


 

Pharmaceutical compositions comprising phenylaminopyrimidine derivative

NºPublicación: AU2016373574A1 12/07/2018

Solicitante:
NATCO PHARMA LTD

Resumen de: AU2016373574A1

An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.



traducir


 

SUPPORT THERAPY FOR ACQUIRED IMMUNODEFICIENCY SYNDROME AND FOR LEUKEMIAS

NºPublicación: EP3345611A1 11/07/2018

Solicitante:
PROBIOTICAL SPA [IT]

Resumen de: EP3345611A1

The present invention relates to a composition for use as support therapy in antitumor chemotherapeutic treatments, in acquired immunodeficiency syndrome treatments and in leukemia treatments. Said composition comprising a bacterial strain belonging to the species Lactobacillus pentosus and having an antiviral and an antibacterial activity, and a highly bioavailable zinc internalized in a tyndalized bacterial cell mixed with at least one rubber, preferably an alginate and/or a gel, preferably a gel.



traducir


 

METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA

NºPublicación: US2018186780A1 05/07/2018

Solicitante:
DANA FARBER CANCER INST INC [US]

Resumen de: WO2015089481A2

The present invention provides compounds of any one of Formulae (I) to (V) (e.g., compounds of any one of Formulae (I-l) to (1-9)), and methods for treating Waldenstrom' s macroglobulinemia (WM) and other B cell neoplams in a subject using the compounds. The methods comprise administering to a subject in need thereof an effective amount of the compounds. Also provided are methods to treat B cell neoplasms using the compounds in combination with inhibitors of Bruton's tyrosine kinase (BTK), interleukin- 1 receptor- associated kinase 1 (IRAKI), interleukin- 1 receptor-associated kinase 4 (IRAK4), bone marrow on X chromosome kinase (BMX), phosphoinositide 3-kinase (PI3K), transforming growth factor b-activated kinase- 1 (TAK1), and/or a Src family kinase.



traducir


 

INHIBITORS OF PROTEIN KINASES

NºPublicación: US2018186783A1 05/07/2018

Solicitante:
PORTOLA PHARM INC [US]

Resumen de: US2018186783A1

The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.



traducir


 

ADULT PLURIPOTENT OLFACTORY STEM CELL AND SEPARATION METHOD THEREFOR AND USE THEREOF

NºPublicación: WO2018120437A1 05/07/2018

Solicitante:
UNIV CHINA MEDICAL [CN]

Resumen de: WO2018120437A1

Provided are an adult pluripotent olfactory stem cell and a separation method therefor and the use thereof. The isolated adult pluripotent olfactory stem cell expresses the B cell-specific Moloney murine leukemia virus insertion site 1.



traducir


 

TREATMENT OF HEMATOLOGICAL MALIGNANCY WITH SMALL MOLECULE NF-KB INHIBITORS

NºPublicación: WO2018125867A1 05/07/2018

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
IMMUNETARGET INC [US]

Resumen de: WO2018125867A1

The disclosure relates to compounds and compositions that inhibit NFKB and are useful in the treatment of hematological malignancies such as lymphoma and myeloma.The present disclosure also provides methods for inhibiting growth and proliferation of cells selected from the group consisting of lymphoma cells and myeloma cells and for the treatment of hematological malignancies using compounds and pharmaceutical compositions capable of inhibiting NF-KB.



traducir


 

KIT FOR TREATING SEPSIS AND/OR ANY SYSTEMIC (SIRS) OR DAMAGING CELLULAR HYPERINFLAMMATION

NºPublicación: US2018185443A1 05/07/2018

Solicitante:
SERENITE FORCEVILLE [FR]

Resumen de: US2018185443A1

Disclosed is a kit including a first container including a composition including at least one antioxidant selenoprotein and at least one second container including at least one composition including at least one oxidant selenocompound. Also disclosed is a method of administration that allows to administer effective and cytotoxic doses of selenocompounds, allowing the inhibition of the hyper-activation of phagocytes and in particular of circulating immature neutrophils and directly and indirectly protects endothelial cells, in particular for the treatment of sepsis, SIRS and leukemia. Further disclosed is an administration device adapted to the administration method.



traducir


 

Antibodies to IL-6 and use thereof

NºPublicación: AU2018204345A1 05/07/2018

Solicitante:
ALDER BIOPHARMACEUTICALS INC

Resumen de: AU2018204345A1

Abstract The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor.



traducir


 

Activin-ActRIIa antagonists and uses for promoting bone growth in cancer patients

NºPublicación: AU2018204248A1 05/07/2018

Solicitante:
ACCELERON PHARMA INC

Resumen de: AU2018204248A1

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.



traducir


 

Methods, reagents and kits for detecting minimal residual disease

NºPublicación: AU2018204429A1 05/07/2018

Solicitante:
ERASMUS UNIV MEDICAL CENTER ROTTERDAM

Resumen de: AU2018204429A1

Title: Methods, reagents and kits for detecting minimal residual disease Abstract The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for > 8-color flow cytometric stainings as well as for 10-color and 12-color flow cytometric stainings, which can reach sensitivities of at least 104, even down to 10-. Also provided are diagnostic kits and methods for detecting MRD.



traducir


 

NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: WO2018122689A1 05/07/2018

Solicitante:
UNIV DEGLI STUDI DI ROMA LA SAPIENZA [IT]
FONDAZIONE ST ITALIANO DI TECNOLOGIA [IT]

Resumen de: WO2018122689A1

Compounds of formula (I) in the capacity of compounds with anti-tumor activity for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).



traducir


 

COMPOSITION INCLUDING ADULT PLURIPOTENT OLFACTORY STEM CELL, METHOD FOR ISOLATING PLURIPOTENT ADULT OLFACTORY STEM CELL, AND USE THEREOF

NºPublicación: US2018187146A1 05/07/2018

Solicitante:
UNIV CHINA MEDICAL [TW]

Resumen de: US2018187146A1

A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).



traducir


 

Compounds useful as kinase inhibitors

NºPublicación: AU2016373530A1 05/07/2018

Solicitante:
LOXO ONCOLOGY INC

Resumen de: AU2016373530A1

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.



traducir


 

NOVEL CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM)

NºPublicación: US2018185324A1 05/07/2018

Solicitante:
ONE WORLD CANNABIS LTD [IL]

Resumen de: US2018185324A1

The present invention discloses a cytotoxic cocktail comprising; (a) a therapeutically effective amount of at least one cannabinoid selected from the group consisting of: cannabidiol (CBD) or a derivative thereof, Tetrahydrocannabinol (THC) or a derivative thereof, and any combination thereof; and (b) at least one therapeutic agent selected from the group consisting of: bortezomib (BTZ), carflizomib (CFZ), lenalidomide (LEN), dexamethasone (DEX), melphalan (MEL) and doxorubicin (DOXO). In a core embodiment the cocktail is conferring a synergistic effect with respect to inhibition or cytotoxicity of multiple myeloma (MM) cells, relative to said at least one therapeutic agent selected from the group consisting of: BTZ, CFZ, LEN, DEX, MEL, DOXO and said CBD and THC, administered separately in a similar concentration.



traducir


 

Method for monitoring the process of acute lymphoblastic leukaemia by means of determination of amino acids

NºPublicación: PL419960A1 02/07/2018

Solicitante:
GDANSKI UNIV MEDYCZNY [PL]

Resumen de: PL419960A1

Przedmiotem zgłoszenia jest sposób oznaczania aminokwasów w osoczu i płynie mózgowo - rdzeniowym. Przedmiotowy sposób oznaczania aminokwasów w materiale biologicznym charakteryzuje się tym, że analiza aminokwasów w materiale jest w następujących etapach: - przygotowanie próbki materiału biologicznego do analizy chromatograficznej, - rozdzielenie następuje poprzez chromatografię cieczową sprzężoną ze spektrometrią mas (LC - MS) - rozdział 21 aminokwasów następuje poprzez chromatografię oddziaływań hydrofilowych HILTC z wykorzystaniem polarnej kolumny, - faza ruchoma składała się z fazy A: 10 mM mrówczan amonu (pH3) w wodzie i B: 10 mM mrówczan amonu w acetonitrylu w warunkach elucji gradientowej, - przepływ fazy ruchomej wynosi 1 ml/min, - temperatura gazu rozpylającego: 250°C, przepływ gazu rozpylającego: 12 L/min, napięcie przyłożone do kapilary: 3 kV, napięcie fragmentacyjne zależne od substancji (zakres od 75 do 125), - czas pojedynczej analizy 21 aminokwasów wraz z równoważeniem kolumny wynosi 30 min, - rozdzielenie aminokwasów nastąpiło w warunkach elucji gradientowej. Zgłoszenie obejmuje też zastosowanie przedmiotowego sposobu do oznaczania aminokwasów u osób chorych na białaczkę limfoblastyczną w momencie postawienia diagnozy oraz podczas chemioterapii.



traducir


 

COMBINATION THERAPY USING BELINOSTAT AND PRALATREXATE TO TREAT LYMPHOMA

Nº publicación: US2018177783A1 28/06/2018

Solicitante:
SPECTRUM PHARMACEUTICALS INC [US]

Resumen de: US2018177783A1

The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver